Morepen Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: MOREPENLAB BSE: 500288

₹125.99

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #53 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Morepen Laboratories Limited (this stock)	6,904	61.5	7.6%	158.1%	0.16%	64	34	55

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹7,087 Cr

EV / EBITDA

36.1x

EV / Sales

3.87x

Market cap / Sales

3.77x

Earnings yield

1.63%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 546 Cr, up 38.2% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	541	72	54	₹0.9900
March 31, 2026	463	28	20	₹0.3700
Dec. 31, 2025	458	31	23	₹0.4300
Sept. 30, 2025	370	19	14	₹0.2600
June 30, 2025	391	11	8	₹0.1500
March 31, 2025	382	17	12	₹0.2000
Dec. 31, 2024	403	30	23	₹0.4100
Sept. 30, 2024	384	43	32	₹0.6000
June 30, 2024	386	47	35	₹0.6900
March 31, 2024	393	53	40	₹0.7800
Dec. 31, 2023	395	47	35	₹0.6900
Sept. 30, 2023	381	27	20	₹0.3900
June 30, 2023	369	22	16	₹0.3100

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	546	472	462	374	395	385	408	388	389	397	398	384	371
Operating revenue	541	463	458	370	391	382	403	384	386	393	395	381	369
Other income	5	9	4	5	4	3	5	5	3	4	4	3	2
Operating expenses	461	439	416	342	372	352	372	341	337	336	344	351	344
Operating profit	80	23	42	28	19	30	32	43	49	56	51	30	25
Operating profit margin	14.7%	5.0%	9.2%	7.6%	4.8%	7.9%	7.8%	11.2%	12.6%	14.3%	13.0%	7.8%	6.7%
Depreciation	8	1	10	11	8	12	5	4	4	7	6	5	5
Interest	5	4	4	4	4	4	1	1	1	1	2	0	0
Exceptional items, gain / (loss)	—	—	—	1	—	—	—	—	—	—	—	—	—
Profit before tax	72	28	31	19	11	17	30	43	47	53	47	27	22
Tax	18	8	8	4	3	5	8	11	12	13	12	7	6
Net profit	—	20	—	14	8	12	23	32	35	40	35	20	16
EPS	0.99	0.37	0.43	0.26	0.15	0.20	0.41	0.60	0.69	0.78	0.69	0.39	0.31
Net profit (TTM)	—	—	—	57	75	102	130	142	130	111	81	59	55
EPS (TTM)	2.05	1.21	1.04	1.02	1.36	1.90	2.48	2.76	2.55	2.17	1.59	1.13	1.09

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	1,681	89	66
March 31, 2025	1,555	138	102
March 31, 2024	1,538	149	111
March 31, 2023	1,339	63	46

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	8.2%	8.7%	1,703^†	1,570^†	1,550^†	1,345^†	1,460^†	1,124^†	801^†	721^†	564^†	—
Operating revenue	7.9%	8.6%	1,681	1,555	1,538	1,339	1,449^†	1,112^†	792^†	717^†	561^†	537^†
Other income	—	—	21^†	16^†	13^†	6^†	10^†	12^†	9^†	4^†	4^†	—
Operating expenses	—	—	1,569^†	1,401^†	1,376^†	1,262^†	1,302^†	1,000^†	728^†	652^†	501^†	471^†
Operating profit	13.2%	-0.1%	112^†	153^†	162^†	77^†	147^†	112^†	64^†	65^†	60^†	66^†
Operating profit margin	—	—	6.7%^†	9.9%^†	10.5%^†	5.8%^†	10.2%^†	10.1%^†	8.1%^†	9.1%^†	10.7%^†	12.3%^†
Depreciation	—	—	29^†	24^†	22^†	18^†	21^†	28^†	34^†	38^†	33^†	34^†
Interest	—	—	16^†	7^†	4^†	2^†	11^†	2^†	2^†	2^†	4^†	7^†
Exceptional items, gain / (loss)	—	—	1^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	12.3%	-1.1%	89	138	149	63	126^†	94^†	37^†	29^†	26^†	23^†
Tax	—	—	23^†	36^†	38^†	17^†	24^†	—	—	—	—	—
Net profit	12.6%	-6.9%	66	102	111	46	101^†	94^†	32^†	29^†	26^†	23^†
EPS	9.6%	-10.4%	1.21^†	1.90^†	2.17^†	0.92^†	2.26^†	2.10^†	0.72^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	6.7%^†	9.9%^†	10.5%^†	5.8%^†	10.2%^†	10.1%^†	8.1%^†	9.1%^†	10.7%^†	12.3%^†
EBIT margin	6.3%^†	9.3%^†	9.9%^†	4.9%^†	9.4%^†	8.6%^†	5.0%^†	4.3%^†	5.4%^†	5.6%^†
PBT margin	5.3%	8.9%	9.7%	4.7%	8.7%^†	8.5%^†	4.7%^†	4.0%^†	4.7%^†	4.3%^†
Net margin	3.9%	6.5%	7.2%	3.5%	7.0%^†	8.5%^†	4.1%^†	4.0%^†	4.7%^†	4.3%^†
Interest coverage	6.55x^†	20.37x^†	43.45x^†	32.83x^†	12.54x^†	50.73x^†	20.05x^†	14.82x^†	7.08x^†	4.30x^†
Dividend payout	16.5%^†	0.0%^†	0.0%^†	0.0%^†	0.0%^†	0.0%^†	0.0%^†	—	—	—
Earnings retention	83.5%^†	100.0%^†	100.0%^†	100.0%^†	100.0%^†	100.0%^†	100.0%^†	—	—	—
Current ratio	3.58x	2.40x	—	—	—	—	—	—	—	—
Quick ratio	3.13x	1.78x	—	—	—	—	—	—	—	—
Debt to equity	0.16x	0.07x	—	—	—	—	—	—	—	—
Return on equity	5.3%	8.6%	—	—	—	—	—	—	—	—
Return on assets	3.5%	5.9%	—	—	—	—	—	—	—	—
Return on capital employed	6.7%^†	11.5%^†	—	—	—	—	—	—	—	—
Asset turnover	0.88x	0.90x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	20	-119	97	84	-63
March 31, 2025	29	-280	260	124	-95
March 31, 2024	77	-84	0	71	6
March 31, 2023	-102	-36	144	36	-138
March 31, 2022	-66	-23	64	45	-112

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,908	1,243	1,133	61	133	1,238	346	11	308	154
March 31, 2025	1,721	1,182	1,072	53	26	1,107	462	24	316	286
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.